Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells (original) (raw)

Abstract

In ovarian carcinoma cells, the combination of interferon-gamma (IFN-gamma) and cisplatin (cDDP) has been reported to result in a synergistic amplification of antiproliferative activity. To assess whether IFN-gamma may also prevent the occurrence of cisplatin resistance, the human ovarian carcinoma cell line HTB-77 was treated repeatedly in an intermittent fashion with either cisplatin alone (HTB-77cDDP) or cisplatin plus IFN-gamma (HTB-77cDDP + IFN). After 8 months of treatment, both new lines (HTB-77cDDP or HTB-77cDDP + IFN) were found to be three times more resistant to cisplatin than the wild-type cells (HTB-77wt). IFN-gamma could not prevent the development of cisplatin resistance. Interestingly, both HTB-77cDDP and HTB-77cDDP + IFN cells were also less IFN-gamma sensitive than the parental line. Both cisplatin-resistant lines expressed p185HER-2 and HER-2 mRNA at a higher concentration than the HTB-77wt cells. IFN-gamma was in all three HTB-77 cell lines able to suppress the HER-2 message and its encoded protein. The expression of IFN-gamma-induced antigens, namely CA-125 and class II antigens of the major histocompatibility complex (HLA-DR), was markedly augmented by IFN-gamma in all three lines, whereby the most prominent effect was seen in HTB-77cDDP and HTB-77cDDP + IFN.

1328

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews P. A., Howell S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 1990 Feb;2(2):35–43. [PubMed] [Google Scholar]
  2. Arteaga C. L., Winnier A. R., Poirier M. C., Lopez-Larraza D. M., Shawver L. K., Hurd S. D., Stewart S. J. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res. 1994 Jul 15;54(14):3758–3765. [PubMed] [Google Scholar]
  3. Chon S. Y., Hassanain H. H., Gupta S. L. Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma-inducible expression of human indoleamine 2,3-dioxygenase gene. J Biol Chem. 1996 Jul 19;271(29):17247–17252. doi: 10.1074/jbc.271.29.17247. [DOI] [PubMed] [Google Scholar]
  4. Guille M. J., Laxton C. D., Rutherford M. N., Williams B. R., Kerr I. M. Functional differences in the promoters of the interferon-inducible (2'-5')A oligoadenylate synthetase and 6-16 genes in interferon-resistant Daudi cells. Eur J Biochem. 1994 Jan 15;219(1-2):547–553. doi: 10.1111/j.1432-1033.1994.tb19970.x. [DOI] [PubMed] [Google Scholar]
  5. Hamaguchi K., Godwin A. K., Yakushiji M., O'Dwyer P. J., Ozols R. F., Hamilton T. C. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res. 1993 Nov 1;53(21):5225–5232. [PubMed] [Google Scholar]
  6. Hancock M. C., Langton B. C., Chan T., Toy P., Monahan J. J., Mischak R. P., Shawver L. K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 1991 Sep 1;51(17):4575–4580. [PubMed] [Google Scholar]
  7. Hayes D. F. Should we treat HER, too? J Clin Oncol. 1996 Mar;14(3):697–699. doi: 10.1200/JCO.1996.14.3.697. [DOI] [PubMed] [Google Scholar]
  8. Langton-Webster B. C., Xuan J. A., Brink J. R., Salomon D. S. Development of resistance to cisplatin is associated with decreased expression of the gp185c-erbB-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line. Cell Growth Differ. 1994 Dec;5(12):1367–1372. [PubMed] [Google Scholar]
  9. Marth C., Gastl G., Zech J., Zilla P., Mayer I., Fasol R., Huber C., Daxenbichler G. Characterization of an interferon-resistant mutant of the human breast cancer cell line BT-20. J Interferon Res. 1987 Apr;7(2):195–202. doi: 10.1089/jir.1987.7.195. [DOI] [PubMed] [Google Scholar]
  10. Marth C., Helmberg M., Mayer I., Fuith L. C., Daxenbichler G., Dapunt O. Effects of biological response modifiers on ovarian carcinoma cell lines. Anticancer Res. 1989 Mar-Apr;9(2):461–467. [PubMed] [Google Scholar]
  11. Marth C., Müller-Holzner E., Greiter E., Cronauer M. V., Zeimet A. G., Doppler W., Eibl B., Hynes N. E., Daxenbichler G. Gamma-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells. Cancer Res. 1990 Nov 1;50(21):7037–7041. [PubMed] [Google Scholar]
  12. Nehme A., Julia A. M., Jozan S., Chevreau C., Bugat R., Canal P. Modulation of cisplatin cytotoxicity by human recombinant interferon-gamma in human ovarian cancer cell lines. Eur J Cancer. 1994;30A(4):520–525. doi: 10.1016/0959-8049(94)90430-8. [DOI] [PubMed] [Google Scholar]
  13. Pietras R. J., Fendly B. M., Chazin V. R., Pegram M. D., Howell S. B., Slamon D. J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 1994 Jul;9(7):1829–1838. [PubMed] [Google Scholar]
  14. Pujade-Lauraine E., Guastalla J. P., Colombo N., Devillier P., François E., Fumoleau P., Monnier A., Nooy M., Mignot L., Bugat R. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol. 1996 Feb;14(2):343–350. doi: 10.1200/JCO.1996.14.2.343. [DOI] [PubMed] [Google Scholar]
  15. Tsai C. M., Levitzki A., Wu L. H., Chang K. T., Cheng C. C., Gazit A., Perng R. P. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res. 1996 Mar 1;56(5):1068–1074. [PubMed] [Google Scholar]
  16. Walker T. L., White J. D., Esdale W. J., Burton M. A., DeCruz E. E. Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. Br J Cancer. 1996 Mar;73(5):610–614. doi: 10.1038/bjc.1996.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Widschwendter M., Daxenbichler G., Dapunt O., Marth C. Effects of retinoic acid and gamma-interferon on expression of retinoic acid receptor and cellular retinoic acid-binding protein in breast cancer cells. Cancer Res. 1995 May 15;55(10):2135–2139. [PubMed] [Google Scholar]
  18. Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N., Saito T., Toyoshima K. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature. 1986 Jan 16;319(6050):230–234. doi: 10.1038/319230a0. [DOI] [PubMed] [Google Scholar]
  19. Zhang L., Hung M. C. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene. 1996 Feb 1;12(3):571–576. [PubMed] [Google Scholar]
  20. van der Zee A. G., Hollema H. H., de Bruijn H. W., Willemse P. H., Boonstra H., Mulder N. H., Aalders J. G., de Vries E. G. Cell biological markers of drug resistance in ovarian carcinoma. Gynecol Oncol. 1995 Aug;58(2):165–178. doi: 10.1006/gyno.1995.1205. [DOI] [PubMed] [Google Scholar]